About Pharmaids Pharmaceuticals Limited
Data last updated: 11 February 2026
Pharmaids Pharmaceuticals Limited is a public limited company based in Bangalore, Karnataka, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 March 1989, the company has been in operation for over 37 years.
Registered with ROC Bangalore under CIN L52520KA1989PLC173979. Listed on BSE: 524572.
Capital: an authorised share capital of ₹101 Cr and a paid-up capital of ₹35.27 Cr. Formerly known as Pharmaids Pharmacuticals Private Limited. It is led by directors including Shreedhara Shetty and Mini Manikantan.
Last AGM: 23 September 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore, Karnataka.
As per the financials filed for FY 2022, the company reported a revenue of ₹3.95 Cr, a decline of 54% compared to the previous year.
The company has a workforce of approximately 21 employees as per the latest available data.
The company is associated with 1 brand - Pharmaids. As per MCA filings, the company has open charges of ₹11.05 Cr and satisfied charges of ₹1.85 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website pharmaids.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressUnit 201 2Nd Floor Brigade Rubix 20/14, Hmt Factory Main Road Peenya Plantation, Bangalore, Karnataka, India – 560013
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L52520KA1989PLC173979, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L52520KA1989PLC173979 | Current |
| U52520AP1989PLC009679 | Previous |
| L52520AP1989PLC009679 | Previous |
| L52520TG1989PLC009679 | Previous |
Associated Brands with Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited operates one associated brand: Pharmaids. These brands represent Pharmaids Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Pharmaids is recognized as a provider of custom research and manufacturing services for pharmaceutical and related industries. | pharmaids.com |
Auditor Details of Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited is audited by PPKG & Co (ICAI peer reviewed, certificate valid till 2029-01-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| PPKG & Co (ICAI peer reviewed, certificate valid till 2029-01-31) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited is currently managed by 9 directors, with 25 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Shreedhara Shetty
Also directs:
Pharmaids Pharmaceuticals Limited, Innovalus Technologies Private Limited, Religent Global Ventures Private Limited and 1 more
|
Director | 29 Aug 2023 | 2 Years 10 Months | Current |
|
Mini Manikantan
Also directs:
Pharmaids Pharmaceuticals Limited
|
Whole-Time Director | 09 Jul 2022 | 4 Years 0 Months | Current |
| Venu Madhava Kaparthy | Whole-Time Director | 21 May 2022 | 4 Years 1 Months | Current |
|
Pattamadai Natarajasarma Vijay
Also directs:
Pharmaids Pharmaceuticals Limited, Jindal Drilling And Industries Limited, Nayara Energy Limited and 2 more
|
Director | 31 Oct 2022 | 3 Years 8 Months | Current |
|
Shankarappa Nagaraja Vinaya Babu
Also directs:
Pharmaids Pharmaceuticals Limited, Bioneeds India Private Limited, Tumkur Trade Center Private Limited and 4 more
|
Director | 31 Jan 2024 | 2 Years 5 Months | Current |
|
Methuku Nagesh
Also directs:
Pharmaids Pharmaceuticals Limited, Adita Bio Sys Private Limited
|
Director | 29 Nov 2022 | 3 Years 7 Months | Current |
Financials of Pharmaids Pharmaceuticals Limited FY 2026 filings available
Pharmaids Pharmaceuticals Limited reported revenue of ₹27.88 Cr (up 43.37% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue from Operations | ₹27.88 Cr | ₹19.45 Cr | ₹15.11 Cr | ₹0 |
| Other Income | ₹28.88 Lakh | ₹10.4 Lakh | ₹87.82 Lakh | ₹0 |
| Total Income | ₹28.17 Cr | ₹19.55 Cr | ₹15.99 Cr | ₹0 |
| Cost of Materials Consumed | ₹14.74 Cr | ₹8.9 Cr | ₹10.27 Cr | ₹0 |
| Purchases of Stock-in-Trade | ₹2.43 Cr | ₹12.79 Cr | ₹4.4 Lakh | ₹0 |
| Changes in Inventories | -₹1.93 Lakh | -₹9.29 Cr | ₹1.16 Cr | ₹88.76 Lakh |
| Employee Benefit Expense | ₹13.38 Cr | ₹13.16 Cr | ₹9.2 Cr | ₹1.13 Cr |
| Finance Costs | ₹3.49 Cr | ₹2.09 Cr | ₹1.57 Cr | ₹46,000 |
| Depreciation & Amortisation | ₹2.03 Cr | ₹2.44 Cr | ₹1.72 Cr | ₹1.68 Lakh |
| Other Expenses | ₹10.89 Cr | ₹6.64 Cr | ₹7.65 Cr | ₹7.87 Cr |
| Total Expenses | ₹46.94 Cr | ₹36.73 Cr | ₹31.61 Cr | ₹9.91 Cr |
| Profit Before Exceptional Items & Tax | -₹18.77 Cr | -₹17.18 Cr | -₹15.62 Cr | -₹9.91 Cr |
| Exceptional Items | ₹2.46 Cr | -₹9.78 Lakh | ₹0 | ₹0 |
| Profit Before Tax | -₹16.3 Cr | -₹17.28 Cr | -₹15.62 Cr | -₹9.91 Cr |
| Total Tax Expense | -₹4.73 Cr | -₹3.77 Cr | -₹3.78 Cr | -₹2.35 Cr |
| Net Profit | -₹11.57 Cr | -₹13.51 Cr | -₹11.84 Cr | -₹7.56 Cr |
| attributable to Owners | -₹11.72 Cr | -₹10.78 Cr | -₹7.97 Cr | - |
| attributable to NCI | ₹14.51 Lakh | -₹2.73 Cr | -₹3.88 Cr | - |
| Other Comprehensive Income | ₹5.08 Lakh | ₹2.05 Lakh | -₹32 Lakh | ₹3.48 Lakh |
| Total Comprehensive Income | -₹11.52 Cr | -₹13.48 Cr | -₹12.16 Cr | -₹7.52 Cr |
| EBITDA (computed) | -₹13.25 Cr | -₹12.65 Cr | -₹12.33 Cr | -₹9.89 Cr |
| Basic EPS | ₹-3.31 | ₹-3.05 | ₹-3.56 | ₹-5.83 |
| Diluted EPS | ₹-3.31 | ₹-3.05 | ₹-3.56 | ₹-5.83 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹87.26 Cr | ₹119.85 Cr | ₹91.34 Cr | ₹24.59 Cr |
| Non-current Assets | ₹76.27 Cr | ₹97.55 Cr | ₹77.81 Cr | ₹7.07 Cr |
| Current Assets | ₹10.99 Cr | ₹22.31 Cr | ₹13.53 Cr | ₹17.51 Cr |
| Property, Plant & Equipment | ₹20.26 Cr | ₹44.65 Cr | ₹31.46 Cr | ₹10.61 Lakh |
| Inventories | ₹41.06 Lakh | ₹12.18 Cr | ₹3.59 Cr | ₹0 |
| Trade Receivables | ₹3.43 Cr | ₹3.13 Cr | ₹2.68 Cr | ₹1.39 Cr |
| Cash & Equivalents | ₹13.35 Lakh | ₹2.14 Cr | ₹4.8 Cr | ₹12.75 Cr |
| Equity (Net Worth) | ₹47.6 Cr | ₹55.04 Cr | ₹70.5 Cr | ₹22.46 Cr |
| Equity Share Capital | ₹35.27 Cr | ₹35.27 Cr | ₹35.27 Cr | ₹21.44 Cr |
| Borrowings (Non-current) | ₹11.84 Cr | ₹30.18 Cr | ₹3.59 Cr | ₹0 |
| Borrowings (Current) | ₹9.07 Cr | ₹5.06 Cr | ₹1.77 Cr | ₹0 |
| Total Debt (computed) | ₹20.91 Cr | ₹35.25 Cr | ₹5.35 Cr | ₹0 |
| Current Liabilities | ₹24.01 Cr | ₹28.71 Cr | ₹11.58 Cr | ₹2.13 Cr |
| Total Liabilities | ₹39.66 Cr | ₹64.81 Cr | ₹20.84 Cr | ₹2.13 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -₹4.06 Cr | -₹13.99 Cr | -₹10.62 Cr | -₹4.01 Cr |
| Investing Cash Flow | ₹23.34 Cr | -₹12.02 Cr | -₹74.99 Cr | -₹4.94 Cr |
| Financing Cash Flow | -₹19.97 Cr | ₹23.36 Cr | ₹77.66 Cr | ₹21.31 Cr |
| Capital Expenditure | ₹4.47 Cr | ₹12.48 Cr | ₹22.86 Cr | ₹1.67 Cr |
| Free Cash Flow (computed) | -₹8.53 Cr | -₹26.47 Cr | -₹33.48 Cr | -₹5.69 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹68.94 Lakh | -₹2.66 Cr | -₹7.95 Cr | ₹12.35 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7.18 Cr | ₹5.43 Cr | ₹8.61 Cr | ₹6.66 Cr | ₹4.77 Cr | ₹4.71 Cr | ₹5.24 Cr | ₹4.67 Cr |
| Other Income | ₹9.92 Lakh | ₹7.6 Lakh | ₹22.15 Lakh | ₹4.01 Lakh | ₹7.4 Lakh | ₹73,200 | ₹1.32 Lakh | ₹94,400 |
| Total Income | ₹7.28 Cr | ₹5.51 Cr | ₹8.83 Cr | ₹6.7 Cr | ₹4.84 Cr | ₹4.72 Cr | ₹5.25 Cr | ₹4.68 Cr |
| Cost of Materials Consumed | ₹1.4 Cr | ₹1.07 Cr | ₹9.84 Cr | ₹1.92 Cr | ₹1.73 Cr | ₹2.04 Cr | ₹2.36 Cr | ₹2.76 Cr |
| Purchases of Stock-in-Trade | ₹47.1 Lakh | ₹42.78 Lakh | ₹45.18 Lakh | ₹1.23 Cr | ₹10.36 Cr | ₹99.01 Lakh | ₹1.1 Cr | ₹33.47 Lakh |
| Changes in Inventories | ₹1.88 Cr | ₹85.12 Lakh | -₹2.74 Cr | ₹35.53 Lakh | -₹9.97 Cr | -₹4.28 Lakh | ₹4.66 Lakh | ₹68.22 Lakh |
| Employee Benefit Expense | ₹2.73 Cr | ₹3.28 Cr | ₹3.18 Cr | ₹4.19 Cr | ₹4.05 Cr | ₹3.25 Cr | ₹2.87 Cr | ₹2.99 Cr |
| Finance Costs | ₹64.95 Lakh | ₹71.79 Lakh | ₹1.08 Cr | ₹1.2 Cr | ₹1.01 Cr | ₹48.46 Lakh | ₹33.46 Lakh | ₹26.13 Lakh |
| Depreciation & Amortisation | ₹47.72 Lakh | ₹47.61 Lakh | ₹46.75 Lakh | ₹60.62 Lakh | ₹62.05 Lakh | ₹63.89 Lakh | ₹61.48 Lakh | ₹56.59 Lakh |
| Other Expenses | ₹1.05 Cr | ₹2.3 Cr | ₹3.2 Cr | ₹4.38 Cr | ₹2.5 Cr | ₹1.35 Cr | ₹1.41 Cr | ₹1.31 Cr |
| Total Expenses | ₹8.65 Cr | ₹9.13 Cr | ₹15.47 Cr | ₹13.87 Cr | ₹10.3 Cr | ₹8.72 Cr | ₹8.75 Cr | ₹8.91 Cr |
| Profit Before Exceptional Items & Tax | -₹1.37 Cr | -₹3.62 Cr | -₹6.65 Cr | -₹7.17 Cr | -₹5.46 Cr | -₹4 Cr | -₹3.49 Cr | -₹4.22 Cr |
| Exceptional Items | -₹8.94 Lakh | -₹39.94 Lakh | ₹2.99 Cr | ₹4,000 | ₹5.99 Lakh | -₹1.19 Lakh | -₹6.95 Lakh | -₹7.63 Lakh |
| Profit Before Tax | -₹1.46 Cr | -₹4.02 Cr | -₹3.66 Cr | -₹7.17 Cr | -₹5.4 Cr | -₹4.01 Cr | -₹3.56 Cr | -₹4.3 Cr |
| Total Tax Expense | -₹37.1 Lakh | -₹1.38 Cr | -₹1.13 Cr | -₹1.86 Cr | -₹59.89 Lakh | -₹99.83 Lakh | -₹1 Cr | -₹1.18 Cr |
| Net Profit | -₹1.09 Cr | -₹2.65 Cr | -₹2.53 Cr | -₹5.32 Cr | -₹4.8 Cr | -₹3.01 Cr | -₹2.56 Cr | -₹3.12 Cr |
| attributable to Owners | -₹1.81 Cr | -₹2.48 Cr | -₹2.84 Cr | -₹4.95 Cr | -₹3.94 Cr | -₹1.93 Cr | -₹2.22 Cr | -₹2.68 Cr |
| attributable to NCI | ₹72.41 Lakh | -₹16.72 Lakh | -₹4.79 Lakh | -₹36.39 Lakh | -₹86.43 Lakh | -₹1.08 Cr | -₹34.31 Lakh | -₹44.02 Lakh |
| Other Comprehensive Income | ₹36,000 | ₹1.91 Lakh | ₹1.91 Lakh | ₹90,000 | ₹2.05 Lakh | ₹700 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.08 Cr | -₹2.63 Cr | -₹2.51 Cr | -₹5.31 Cr | -₹4.78 Cr | -₹3.01 Cr | -₹2.56 Cr | -₹3.12 Cr |
| EBITDA (computed) | -₹23.99 Lakh | -₹2.43 Cr | -₹5.1 Cr | -₹5.37 Cr | -₹3.83 Cr | -₹2.88 Cr | -₹2.54 Cr | -₹3.4 Cr |
| Basic EPS | ₹-0.51 | ₹-0.70 | ₹-0.70 | ₹-1.41 | ₹-1.11 | ₹-0.55 | ₹-0.73 | ₹-0.76 |
| Diluted EPS | ₹-0.51 | ₹-0.70 | ₹-0.70 | ₹-1.41 | ₹-1.11 | ₹-0.55 | ₹-0.73 | ₹-0.76 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹10.6 Cr | ₹2.34 Cr | ₹2.78 Lakh | ₹0 | ₹3.94 Cr | ₹8.55 Cr | ₹0 | ₹48.1 Lakh |
| Other Income | ₹66.04 Lakh | ₹1.02 Cr | ₹79.5 Lakh | ₹0 | ₹1.51 Lakh | ₹2.63 Lakh | ₹0 | ₹52,000 |
| Total Income | ₹11.26 Cr | ₹3.36 Cr | ₹82.27 Lakh | - | ₹3.95 Cr | ₹8.58 Cr | ₹0 | ₹48.62 Lakh |
| Cost of Materials Consumed | ₹10.91 Cr | ₹3.01 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹39.6 Lakh | ₹11.52 Cr | ₹25.42 Lakh | ₹0 | ₹4.09 Cr | ₹8.53 Cr | ₹0 | ₹35.62 Lakh |
| Changes in Inventories | ₹11.5 Lakh | -₹9.54 Cr | -₹22.93 Lakh | ₹88.76 Lakh | -₹51.85 Lakh | -₹36.91 Lakh | ₹0 | ₹0 |
| Employee Benefit Expense | ₹5.4 Cr | ₹3.42 Cr | ₹1.99 Cr | ₹1.13 Cr | ₹10.44 Lakh | ₹4.43 Lakh | ₹2.28 Lakh | ₹2.83 Lakh |
| Finance Costs | ₹3.3 Cr | ₹2.15 Cr | ₹33.34 Lakh | ₹46,000 | ₹27,000 | ₹0 | ₹8,000 | ₹5,000 |
| Depreciation & Amortisation | ₹21.38 Lakh | ₹19.95 Lakh | ₹17.72 Lakh | - | ₹92,000 | ₹4.48 Lakh | ₹3.88 Lakh | ₹14,000 |
| Other Expenses | ₹7.99 Cr | ₹4.17 Cr | ₹4.39 Cr | ₹7.87 Cr | ₹12.63 Lakh | ₹24.08 Lakh | ₹31.28 Lakh | ₹24.75 Lakh |
| Total Expenses | ₹28.33 Cr | ₹11.95 Cr | ₹6.91 Cr | ₹9.91 Cr | ₹3.81 Cr | ₹8.49 Cr | ₹37.52 Lakh | ₹63.39 Lakh |
| Profit Before Exceptional Items & Tax | -₹17.06 Cr | -₹8.59 Cr | -₹6.09 Cr | - | ₹14.03 Lakh | ₹8.84 Lakh | -₹37.52 Lakh | -₹14.77 Lakh |
| Exceptional Items | ₹3.11 Cr | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹13.95 Cr | -₹8.59 Cr | -₹6.09 Cr | -₹9.91 Cr | ₹14.03 Lakh | ₹8.84 Lakh | -₹37.52 Lakh | -₹14.77 Lakh |
| Total Tax Expense | -₹3.52 Cr | -₹1.31 Cr | -₹1.14 Cr | -₹2.35 Cr | -₹49,000 | -₹48,800 | -₹40.87 Lakh | ₹0 |
| Net Profit | -₹10.44 Cr | -₹7.28 Cr | -₹4.95 Cr | -₹7.56 Cr | ₹14.52 Lakh | ₹9.33 Lakh | ₹3.35 Lakh | -₹18.47 Lakh |
| Other Comprehensive Income | ₹2.89 Lakh | ₹70,000 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹10.41 Cr | -₹7.27 Cr | -₹4.95 Cr | - | ₹14.52 Lakh | ₹9.33 Lakh | ₹3.35 Lakh | -₹18.47 Lakh |
| EBITDA (computed) | -₹13.55 Cr | -₹6.24 Cr | -₹5.58 Cr | - | ₹15.22 Lakh | ₹13.33 Lakh | -₹33.56 Lakh | -₹14.58 Lakh |
| Basic EPS | ₹-2.95 | ₹-2.06 | ₹-2.18 | - | ₹0.14 | ₹0.09 | ₹0.03 | ₹-0.54 |
| Diluted EPS | ₹-2.95 | ₹-2.06 | ₹-2.18 | - | ₹0.14 | ₹0.09 | ₹0.03 | ₹-0.54 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹83.96 Cr | ₹118.69 Cr | ₹85 Cr | ₹24.55 Cr | ₹11.11 Cr | ₹9.12 Cr | ₹8.46 Cr | ₹1.04 Cr |
| Non-current Assets | ₹78.14 Cr | ₹106.01 Cr | ₹80.24 Cr | ₹6.41 Cr | ₹8.44 Cr | ₹8.26 Cr | ₹8.07 Cr | ₹39.93 Lakh |
| Current Assets | ₹5.82 Cr | ₹12.68 Cr | ₹4.76 Cr | ₹18.15 Cr | ₹2.67 Cr | ₹85.73 Lakh | ₹38.73 Lakh | ₹64.29 Lakh |
| Property, Plant & Equipment | ₹7.91 Cr | ₹24.18 Cr | ₹16.55 Cr | - | ₹3.06 Lakh | ₹3.98 Lakh | ₹8.31 Lakh | ₹25,000 |
| Inventories | ₹0 | ₹9.77 Cr | ₹22.93 Lakh | ₹0 | ₹88.76 Lakh | ₹36.91 Lakh | ₹0 | ₹0 |
| Trade Receivables | ₹1.38 Cr | ₹15.62 Lakh | ₹0 | - | ₹1.34 Cr | ₹27.72 Lakh | ₹0 | ₹53.62 Lakh |
| Cash & Equivalents | ₹10.79 Lakh | ₹46.93 Lakh | ₹2.46 Cr | ₹0 | ₹40.75 Lakh | ₹20.03 Lakh | ₹2.18 Lakh | ₹10.67 Lakh |
| Equity (Net Worth) | ₹53.38 Cr | ₹63.79 Cr | ₹71.06 Cr | - | ₹8.67 Cr | ₹8.53 Cr | ₹8.43 Cr | ₹85.73 Lakh |
| Equity Share Capital | ₹35.27 Cr | ₹35.27 Cr | ₹35.27 Cr | - | ₹10.27 Cr | ₹10.27 Cr | ₹10.27 Cr | ₹3.36 Cr |
| Borrowings (Non-current) | ₹14.91 Cr | ₹39.4 Cr | ₹12.5 Cr | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹5.54 Cr | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹20.45 Cr | ₹39.4 Cr | ₹12.5 Cr | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹15.64 Cr | ₹15.23 Cr | ₹1.1 Cr | ₹2.13 Cr | ₹2.44 Cr | ₹58.86 Lakh | ₹2.51 Lakh | ₹18.49 Lakh |
| Total Liabilities | ₹30.58 Cr | ₹54.9 Cr | ₹13.94 Cr | - | ₹2.44 Cr | ₹58.86 Lakh | ₹2.51 Lakh | ₹18.49 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹3.53 Cr | -₹7.72 Cr | -₹3.44 Cr | -₹4.02 Cr | -₹25.93 Lakh |
| Investing Cash Flow | ₹24.53 Cr | -₹18.9 Cr | -₹72.51 Cr | -₹4.94 Cr | ₹46.65 Lakh |
| Financing Cash Flow | -₹21.36 Cr | ₹24.64 Cr | ₹65.66 Cr | ₹21.31 Cr | ₹0 |
| Capital Expenditure | ₹2.48 Cr | ₹9.04 Cr | ₹16.37 Cr | - | ₹0 |
| Free Cash Flow (computed) | -₹6.01 Cr | -₹16.76 Cr | -₹19.82 Cr | - | -₹25.93 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹36.14 Lakh | -₹1.99 Cr | -₹10.29 Cr | ₹12.35 Cr | ₹20.72 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2.69 Cr | ₹83.28 Lakh | ₹5.97 Cr | ₹1.12 Cr | ₹13.25 Lakh | ₹1.21 Cr | ₹83.4 Lakh | ₹16.65 Lakh |
| Other Income | ₹6.16 Lakh | ₹6.09 Lakh | ₹19.06 Lakh | ₹34.72 Lakh | ₹1.01 Cr | ₹38,400 | ₹51,100 | ₹31,200 |
| Total Income | ₹2.75 Cr | ₹89.37 Lakh | ₹6.16 Cr | ₹1.46 Cr | ₹1.14 Cr | ₹1.21 Cr | ₹83.91 Lakh | ₹16.96 Lakh |
| Cost of Materials Consumed | ₹71.65 Lakh | ₹33.17 Lakh | ₹9.29 Cr | ₹5.94 Lakh | ₹2.99 Lakh | ₹1,000 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹54.72 Lakh | ₹9.88 Cr | ₹80.35 Lakh | ₹61.5 Lakh | ₹21.7 Lakh |
| Changes in Inventories | ₹1.92 Cr | ₹87.16 Lakh | -₹2.77 Cr | ₹45.71 Lakh | -₹9.77 Cr | ₹25.53 Lakh | ₹4.1 Lakh | -₹6.7 Lakh |
| Employee Benefit Expense | ₹85.24 Lakh | ₹1.55 Cr | ₹1.6 Cr | ₹1.4 Cr | ₹1.09 Cr | ₹86.66 Lakh | ₹71.71 Lakh | ₹73.96 Lakh |
| Finance Costs | ₹59.96 Lakh | ₹57.17 Lakh | ₹1.02 Cr | ₹1.11 Cr | ₹2.05 Cr | ₹6.99 Lakh | ₹1.28 Lakh | ₹1.28 Lakh |
| Depreciation & Amortisation | ₹5.27 Lakh | ₹5.36 Lakh | ₹5.65 Lakh | ₹5.1 Lakh | ₹5.25 Lakh | ₹4.96 Lakh | ₹4.96 Lakh | ₹4.78 Lakh |
| Other Expenses | ₹28.15 Lakh | ₹1.76 Cr | ₹2.43 Cr | ₹3.53 Cr | ₹1.57 Cr | ₹1.01 Cr | ₹59 Lakh | ₹99.4 Lakh |
| Total Expenses | ₹4.42 Cr | ₹5.13 Cr | ₹11.62 Cr | ₹7.15 Cr | ₹4.92 Cr | ₹3.06 Cr | ₹2.03 Cr | ₹1.94 Cr |
| Profit Before Exceptional Items & Tax | -₹1.67 Cr | -₹4.24 Cr | -₹5.46 Cr | -₹5.69 Cr | -₹3.78 Cr | -₹1.85 Cr | -₹1.19 Cr | -₹1.77 Cr |
| Exceptional Items | -₹2.04 Lakh | ₹0 | ₹3.13 Cr | ₹3,000 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹1.69 Cr | -₹4.24 Cr | -₹2.33 Cr | -₹5.69 Cr | -₹3.78 Cr | -₹1.85 Cr | -₹1.19 Cr | -₹1.77 Cr |
| Total Tax Expense | -₹37.87 Lakh | -₹1.13 Cr | -₹68.15 Lakh | -₹1.33 Cr | -₹72.47 Lakh | -₹25.22 Lakh | -₹17.97 Lakh | -₹15.12 Lakh |
| Net Profit | -₹1.31 Cr | -₹3.11 Cr | -₹1.65 Cr | -₹4.36 Cr | -₹3.06 Cr | -₹1.59 Cr | -₹1.01 Cr | -₹1.62 Cr |
| Other Comprehensive Income | ₹2.35 Lakh | ₹18,000 | ₹17,000 | ₹18,000 | ₹70,000 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.29 Cr | -₹3.11 Cr | -₹1.65 Cr | -₹4.36 Cr | -₹3.05 Cr | -₹1.59 Cr | -₹1.01 Cr | -₹1.62 Cr |
| EBITDA (computed) | -₹1.02 Cr | -₹3.61 Cr | -₹4.39 Cr | -₹4.53 Cr | -₹1.68 Cr | -₹1.73 Cr | -₹1.12 Cr | -₹1.71 Cr |
| Basic EPS | ₹-0.37 | ₹-0.88 | ₹-0.47 | ₹-1.24 | ₹-0.86 | ₹-0.45 | ₹-0.29 | ₹-0.46 |
| Diluted EPS | ₹-0.37 | ₹-0.88 | ₹-0.47 | ₹-1.24 | ₹-0.86 | ₹-0.45 | ₹-0.29 | ₹-0.46 |
Shareholding Pattern of Pharmaids Pharmaceuticals Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 32.99%, retail and other public shareholders hold 67.01% of Pharmaids Pharmaceuticals Limited. The company had 8,406 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 32.99% | 32.99% | 32.99% | 5.14% | 5.22% | 5.22% |
| Public | 67.01% | 67.01% | 67.01% | 94.86% | 94.78% | 94.78% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 32.99% | 5.22% | 5.64% |
| Public | 67.01% | 94.78% | 94.36% |
| Promoter change (YoY, %pts) | +27.77 | -0.42 | - |
Charges & Borrowings of Pharmaids Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2025 | Axis Bank Limited | ₹6.75 Cr | Open |
| 25 Sep 2025 | State Bank of India | ₹4.3 Cr | Open |
| 15 Sep 2015 | Others | ₹1 Cr | Satisfied |
| 10 Sep 1996 | Central Bank of India | ₹5 Lakh | Satisfied |
| 31 Jul 1995 | Central Bank of India | ₹30 Lakh | Satisfied |
Total charge records: 7 View all charges
Employees and EPFO Compliance at Pharmaids Pharmaceuticals Limited
View historical data on people associated with Pharmaids Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Pharmaids Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Pharmaids Pharmaceuticals Limited
GSTIN & GST Filing Data of Pharmaids Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Pharmaids Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Pharmaids Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Pharmaids Pharmaceuticals Limited
MSME Payment Delays by Pharmaids Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Pharmaids Pharmaceuticals Limited
Subsidiaries & Group Companies of Pharmaids Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Pharmaids Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Pharmaids Pharmaceuticals Limited
MCA Filings & Documents of Pharmaids Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Pharmaids Pharmaceuticals Limited
Recent News on Pharmaids Pharmaceuticals Limited
Frequently Asked Questions about Pharmaids Pharmaceuticals Limited
Pharmaids Pharmaceuticals Limited is an active public limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 01 March 1989 (37+ years old) and is registered under CIN L52520KA1989PLC173979. Listed on BSE: 524572. The company has 21 employees.
Pharmaids Pharmaceuticals Limited reported revenue of ₹3.95 Cr for FY 2022 (down 54.00% YoY).
The current directors of Pharmaids Pharmaceuticals Limited are:
- Shreedhara Shetty
- Mini Manikantan
- Prasanna Subramanya Bhat
- Balagangadhara Bidanagere Channathimmaiah
- Venu Madhava Kaparthy
- Pattamadai Natarajasarma Vijay
- Shankarappa Nagaraja Vinaya Babu
- Methuku Nagesh
- Yogananda Moolemath
The primary industry of Pharmaids Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Pharmaids Pharmaceuticals Limited is listed on BSE with code 524572.
Pharmaids Pharmaceuticals Limited can be reached at the registered office: Unit 201 2Nd Floor Brigade Rubix 2014, Hmt Factory Main Road Peenya Plantation, Bangalore, Karnataka, India – 560013, or through the website pharmaids.com.